Table 1.
Clinicopathological characteristics of patients enrolled in our cohort.
| Characteristics | HHLA2 Low N=63 | HHLA2 High N=18 | P value |
|---|---|---|---|
| Age | 0.155 | ||
| <60 | 49 (81.7) | 11 (18.3) | |
| ≥60 | 14 (66.7) | 7 (33.3) | |
| Gender | 0.282 | ||
| Male | 37 (82.2) | 8 (17.8) | |
| Female | 26 (72.2) | 10 (27.8) | |
| ECOG PS | 0.676 | ||
| 0 | 55 (76.4) | 17 (23.6) | |
| 1-2 | 8 (88.9) | 1 (11.1) | |
| LDH | 0.724 | ||
| Normal | 51 (76.1) | 16 (23.9) | |
| Elevated | 12 (85.7) | 2 (14.3) | |
| Subtype | 0.424 | ||
| Cutaneous | 30 (76.9) | 9 (23.1) | |
| Acral | 21 (72.4) | 8 (27.6) | |
| Mucosal | 12 (92.3) | 1 (7.7) | |
| Tumor stage | 1.000 | ||
| Stage III | 4 (80.0) | 1 (20.0) | |
| Stage IV | 59 (77.6) | 17 (22.4) | |
| Liver metastasis | 0.175 | ||
| No | 50 (74.6) | 17 (25.4) | |
| Yes | 13 (92.9) | 1 (1.2) | |
| Brain metastasis | 0.677 | ||
| No | 56 (76.7) | 17 (23.3) | |
| Yes | 7 (87.5) | 1 (12.5) | |
| Line of systematic treatment | 0.538 | ||
| First | 46 (75.4) | 15 (85.0) | |
| Second | 17 (24.6) | 3 (15.0) | |
| Type of immunotherapy | 0.548 | ||
| Anti-PD-1/PD-L1/CTLA4 monotherapy | 23 (76.7) | 7 (23.3) | |
| Anti-PD-1/PD-L1+ Anti-CTLA-4 therapy | 6 (66.7) | 3 (33.3) | |
| Anti-PD-1/PD-L1+ other therapies | 34 (81.0) | 8 (19.0) |
*P values <0.05 in bold are statistically significant.
HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenases; PD-1, programmed cell death protein-1; PD-L1, programmed death 1 ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.